



COMMUNICATIONS ASCO 2025 CHU DE TOULOUSE

Poster Session

QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in *FLT3*-ITD–negative acute myeloid leukemia (AML).

Pau Montesinos, June-Won Cheong, Naval G. Daver, Amir Fathi, Mark J. Levis, Selina M. Luger, Toshihiro Miyamoto, Esther N. Oliva, Alexander E. Perl, **Christian Recher**, Richard F. Schlenk, Jianxiang Wang, Amer M. Zeidan, Li Liu, Yvonne Duong, Karima Imadalou, Karenza Alexis, Akash Nahar, Kristy Burns, Harry P. Erba

Prognostic factors of survival and recurrence after liver transplantation for unresectable colorectal liver metastases: Results from the TransMet trial.

Rene Adam, Kawther Nheri, Laurence Chiche, Ephrem Salamé, Olivier Scatton, Victoire Granger, Michel P. Ducreux, Umberto Cillo, Francois Cauchy, Jean-Yves Mabrut, Chris Verslype, Laurent Coubeau, Jean Hardwigsen, Emmanuel Boleslawski, **Fabrice Muscari**, Jan Lerut, Francis A. Lévi, Maité Lewin, Lamiae Grimaldi, Maximiliano Gelli, TRANSMET Collaborative Study Group

Immune checkpoint inhibitor (ICI) reuse after failure of first-line ICI in patients with metastatic dMMR/MSI gastrointestinal cancers: The INFLATE study.

Léa Mercier, Filippo Pietrantonio, Edouard Auclin, Michael J. Overman, **Emily L. Alouani**, Antoine Hollebecque, Sara Lonardi, Frank A. Sinicrope, David Tougeron, Marie Duthelage, Anthony Turpin, Thibault Mazard, Francesco Sclafani, Priya Jayachandran, Javier Ros Montaña, Lola Jade Palmieri, **Rosine Guimbaud**, Julien Taieb, Simon Pernot

Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations.

Anas Gazzah, Chia-Chi Lin, Gerrina Ruiter, Pilar Garrido, **Julien Mazieres**, Enriqueta Felip, Yung-Hung Luo, David R. Spigel, Sandrine Hirt, Ki Hyeong Lee, Allegra Mondillo, Marie Bernardo, Ming Lin, Bill Bradley, Simon Roberts, Raymond Pagliarini, Jin Xu, Mark Chao, Danny Nguyen, Alex Spira

IMMUNORARE⁵: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The B3 Thymomas and Thymic Carcinomas Cohort.

Michaël Duruisseaux, Benjamin Besse, Nicolas Girard, Eric Dansin, Sophie Cousin, Julien Mazieres, Ludovic Doucet, Anne Madroszyk, Laurent Greillier, Charles Ricordel, Sarah Cavaillon, Celine Mascaux, Cécile Vicier, Diego Tosi, Sara Calattini, Vérane Schwiertz, Sylvie Bin, Fabien Subtil, Benoit You, Thomas Pierret

Oral Abstract Session

MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial.

Aurore Perrot, Cyrille Hulin, Jerome Lambert, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean Marc Schiano de Colella, Mohamad Mohty, Xavier P. Leleu, Salomon Manier, Herve Avet-Loiseau, Jill Corre, Philippe Moreau, Cyrille Touzeau

Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial.

Philippe Moreau, Pieter Sonneveld, Hermann Einsele, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier P. Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Huiling Pei, Anna Sitthi-Amorn, Robin L. Carson, Meletios A. Dimopoulos, Paula Rodríguez-Otero, Mario Boccadoro

First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.

Niels W. van de Donk, Gala Vega, Aurore Perrot, Sébastien Anguille, Albert Oriol, Monique Minnema, Martin F. Kaiser, Hans C. Lee, Alfred Garfall, Jeffrey V. Matous, Larysa J. Sanchez, Azra Borogovac, Lionel Karlin, Saad Z. Usmani, Joseph Weidman, Sangmin Lee, Maria-Victoria Mateos, Paula Rodríguez-Otero, Cyrille Touzeau, Rakesh Popat

Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE).

Andreas Hochhaus, François-Xavier Mahon, Tim H. Brümmendorf, Phillipp D. Le Coutre, David J. Andorsky, Susanne Saussele, Stephen Strickland, Thomas Cluzeau, Françoise Huguet, Jiří Mayer, Viviane Dubruille, Dong-Wook Kim, Ilina Micheva,

Gabrielle Roth Guepin, Virginia Pilipovic, Jacqueline Ryan, Nabil Amirouchene Angelozzi, Nithya Agrawal, Ennan Gu, Delphine Réa

Rapid Oral Abstract Session

Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.

Nicolas Girard, Benjamin Besse, Michaël Duruisseaux, Laurent Greillier, Thierry Berghmans, Nuria Pardo, Sanjay Popat, Radj Gervais, Santiago Ponce Aix, Annelies Janssens, Sjaak Burgers, Joachim Aerts, **Julien Mazieres**, Yvonne J. Summers, Anne-Claire Toffart, Anne-sophie Govaerts, Eleni Xenophontos, Luc Boone, Solange Peters

Publication Only

Omission of elective neck irradiation in pT3-T4 oral squamous cell carcinoma with a pN0 neck: Impact on regional control and overall survival.

Mathilde Mirallie, Anoushka Modesto, **Marie Christelle Pajiep Chapda**, Jean-Pierre Delord, **Sebastien Vergez**, Lucie Piram, Céline Dalmasso, Emilien Chabrilac, **Agnès Dupret-Bories**